Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Proof-of-concept Parallel Group Clinical Trial to Investigate the Efficacy, Safety and Tolerability of Weekly Subcutaneous Dosing of CK-0045 in Participants With Overweight/Obesity and Type 2 Diabetes

NCT06611930 is registered in ClinicalTrials.gov with Cytoki Pharma as lead sponsor.

NCT NCT06611930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06611930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Proof-of-concept Parallel Group Clinical Trial to Investigate the Efficacy, Safety and Tolerability of Weekly Subcutaneous Dosing of CK-0045 in Participants With Overweight/Obesity and Type 2 Diabetes
Lead sponsor
Cytoki Pharma
Phase
Phase 2
Overall status
Terminated
Start date
September 6, 2024
Completion date
October 21, 2025
Enrollment
90 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight, type 2 diabetes mellitus (t2dm)